New Two-Drug cocktail shows promise against tough cancers
NCT ID NCT04332653
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The trial included several cancer types, such as lung, breast, pancreatic, and ovarian cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)
What this could lead to
If it works, this combination could offer a new treatment option for several hard-to-treat cancers that have stopped responding to standard therapy.
What could go wrong
This is an early-phase study (1b/2a) with a small number of participants, so results may not apply to everyone. The drugs can cause serious side effects, and the combination may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Moffit Cancer Center
Tampa, Florida, 33612, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37211, United States
-
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110, United States